Table 4.
CHIPRA measures of recommended care receipt in the 18 months after intervention
| Intent to Treat (ITT) | Effect of Treatment on the Treated (ETOT)(Intervention clinic patients only) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Intervention clinic patients N = 15024 |
Control clinic patients N = 12227 | Patients with tool use N = 2240 |
Patients without tool use N = 12784 |
|||||||
| N eligible | N (%) received | N eligible | N (%) received |
Adjusted OR (95% CI) | N eligible | N (%) received | N eligible | N (%) received | Adjusted OR (95% CI) | |
| Well-child visits in first 15 monthsa | 1141 | 483 (42.3) | 1078 | 570 (52.9)** | 0.57 (0.38, 0.85) | 161 | 101 (62.7) | 980 | 382 (39.0)** | 1.54 (1.06, 2.25) |
| Well-child visit in 3rd-6th yearb | 4367 | 3926 (89.9) | 3753 | 3389 (90.3) | 1.09 (0.94, 1.26) | 670 | 638 (95.2) | 3697 | 3288 (88.9)** | 1.44 (0.84, 2.46) |
| Adolescent well-care visitc | 5899 | 5065 (85.9) | 4429 | 3806 (85.9) | 1.05 (0.71, 1.55) | 917 | 824 (89.9) | 4982 | 4241 (85.1)** | 1.06 (0.82, 1.38) |
| BMI assessment for children/adolescentsd | 12101 | 11610 (95.9) | 9581 | 9243 (96.5)* | 0.81 (0.58, 1.14) | 1927 | 1857 (96.4) | 10,174 | 9753 (95.9) | 1.07 (0.97, 1.18) |
| Human papillomavirus vaccine for female adolescents (HPV)e | 927 | 358 (38.6) | 689 | 262 (38.0) | 1.10 (0.74, 1.64) | 141 | 76 (53.9) | 786 | 282 (35.9)** | 1.44 (1.12, 1.84) |
| Chlamydia screening in womenf | 1596 | 450 (28.2) | 1263 | 565 (44.7)** | 0.49 (0.36, 0.70) | 228 | 65 (28.5) | 1368 | 385 (28.1) | 1.24 (0.94, 1.62) |
| Childhood immunization statusg | ||||||||||
| Diphtheria, tetanus and pertussis (DTaP)h | 1891 | 1458 (77.1) | 1727 | 1362 (78.9) | 0.92 (0.74, 1.15) | 286 | 256 (89.5) | 1605 | 1202 (74.9)** | 1.38 (1.09, 1.74) |
| Inactivated polio (IPV)i | 1891 | 1670 (88.3) | 1727 | 1514 (87.7) | 1.13 (0.87, 1.48) | 286 | 277 (96.9) | 1605 | 1393 (86.8)** | 1.73 (0.83, 3.60) |
| Measles-Mumps-Rubella (MMR)j | 1891 | 533 (28.2) | 1727 | 656 (38.0)** | 0.61 (0.43, 0.86) | 286 | 92 (32.2) | 1605 | 441 (27.5) | 1.10 (0.69, 1.77) |
| Haemophilus influenza type b (Hib)k | 1891 | 1681 (88.9) | 1727 | 1517 (87.8) | 1.23 (0.94, 1.60) | 286 | 278 (97.2) | 1605 | 1403 (87.4)** | 1.83 (0.78, 4.26) |
| Hepatitis Bl | 1891 | 1697 (89.7) | 1727 | 1544 (89.4) | 1.15 (0.79, 1.69) | 286 | 279 (97.6) | 1605 | 1418 (88.4)** | 2.03 (0.92, 4.44) |
| Varicella zoster virus (VZV)m | 1891 | 1655 (87.5) | 1727 | 1516 (87.8) | 1.12 (0.76, 1.66) | 286 | 269 (94.1) | 1605 | 1386 (86.4)** | 1.13 (0.74, 1.73) |
| Pneumococcal conjugate (PCV)n | 1891 | 1424 (75.3) | 1727 | 1258 (72.8) | 1.20 (0.95, 1.52) | 286 | 249 (87.1) | 1605 | 1175 (73.2)** | 1.20 (0.87, 1.65) |
| Hepatitis Ao | 1891 | 1640 (86.7) | 1727 | 1515 (87.7) | 1.04 (0.71, 1.53) | 286 | 268 (93.7) | 1605 | 1372 (85.5)** | 1.10 (0.79, 1.53) |
| Rotavirus (RV)p | 1891 | 1249 (66.1) | 1727 | 1088 (63.0) | 1.13 (0.89, 1.45) | 286 | 233 (81.5) | 1605 | 1016 (63.3)** | 1.45 (1.03, 2.04) |
| Influenzaq | 1891 | 850 (44.9) | 1727 | 807 (46.7) | 0.91 (0.73, 1.13) | 286 | 177 (61.9) | 1605 | 673 (41.9)** | 1.47 (1.16, 1.86) |
| Combination 10qr | 1891 | 211 (11.2) | 1727 | 243 (14.1)* | 0.74 (0.38, 1.43) | 286 | 51 (17.8) | 1605 | 160 (10.0)** | 1.22 (0.72, 2.05) |
| Immunizations for adolescentss | ||||||||||
| Meningococcalt | 1837 | 1400 (76.2) | 1352 | 999 (73.9) | 1.36 (1.00, 1.86) | 304 | 255 (83.9) | 1533 | 1145 (74.7)** | 1.06 (0.78, 1.45) |
| Tetanus, diphtheria, pertussis/Tetanus, diphtheria (Tdap/Td)u | 1837 | 1485 (80.8) | 1352 | 1020 (75.4)** | 1.65 (1.26, 2.15) | 304 | 261 (85.9) | 1533 | 1224 (79.8)* | 0.93 (0.77, 1.12) |
| Combination 1v | 1837 | 1355 (73.8) | 1352 | 903 (66.8)** | 1.65 (1.23, 2.21) | 304 | 243 (79.9) | 1533 | 1112 (72.5)* | 0.93 (0.70, 1.23) |
* χ2 Tests of independence p < .05
** χ2 Tests of independence p < .001
Odds ratios from logistic GEE model accounting for clustering within clinic, adjusted for sex (where appropriate), age (where appropriate), race/ethnicity, primary language, FPL, new vs. established patient status, family member on Medicaid case (Y/N), and length of time family had been established with the clinic
BOLD = adjusted odds ratio significantly different from 1.0 (p < .05)
apercentage of children aged 15 months with ≥6 well-child visits in first 15 months of life
bpercentage of children ages 3 to 6 with ≥1 well-child visis
cpercentage of children ages 12 to 21 with ≥1 comprehensive well-care visit
dpercentage of children ages 3 to 17 with BMI documentation
epercentage of females aged 13 years with 3 doses of HPV vaccine by their 13th birthday
fpercentage of sexually active females ages 16 to 20 with ≥1 test for chlamydia
gpercentage of children aged 2 years with specific vaccines by their second birthday
h≥4 DTaP vaccinations with different dates of service, ≥42 days after birth
i≥3 IPV vaccinations with different dates of service, ≥42 days after birth
j≥1 MMR vaccine; or ≥ 1 measles & rubella vaccine plus 1 mumps vaccine; or ≥ 1 measles, ≥1 mumps, & ≥1 rubella vaccine
k≥3 Hib vaccinations with different dates of service, ≥42 days after birth
l≥3 HepB vaccinations with different dates of service
m≥1 VZV vaccination or history of varicella zoster
n≥4 PCV vaccinations with different dates of service, ≥42 days after birth
o≥1 HepA vaccination or history of HepA illness
p≥2 doses of 2-dose RV on different dates; or ≥ 3 doses of 3-dose RV on different dates; or ≥ 1 dose of 2-dose RV + ≥2 doses of 3-dose RV on different dates of service; ≥42 days after birth
q≥2 flu vaccinations with different dates of service, ≥180 days after birth
rchildren who were numerator compliant for all 10 above vaccinations
spercentage of adolescents aged 13 with specific vaccines by their 13th birthday
t≥1 meningococcal vaccination between 11th and 13th birthdays
u≥1 Tdap; or ≥ 1 Td; or ≥ 1 tetanus and ≥ 1 diphtheria between 10th and 13th birthdays
vadolescents who were numerator compliant for both above vaccinations